Posthuma EF - Search Results

1

Proteosomal degradation of BCR/ABL protein can generate an HLA-A*0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated.

Posthuma EF, van Bergen CA, Kester MG, de Paus RA, van Veelen PA, de Ru AH, Drijfhout JW, Lurvink EG, Willemze R, Falkenburg JH. Posthuma EF, et al. Haematologica. 2004 Sep;89(9):1062-71. Haematologica. 2004. PMID: 15377467

2

HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT.

Posthuma EF, Falkenburg JH, Apperley JF, Gratwohl A, Roosnek E, Hertenstein B, Schipper RF, Schreuder GM, D'Amaro J, Oudshoorn M, van Biezen JH, Hermans J, Willemze R, Niederwieser D. Posthuma EF, et al. Blood. 1999 Jun 1;93(11):3863-5. Blood. 1999. PMID: 10339494 Free article.

3

HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry.

Posthuma EF, Falkenburg JH, Apperley JF, Gratwohl A, Hertenstein B, Schipper RF, Oudshoorn M, Biezen JH, Hermans J, Willemze R, Roosnek E, Niederwieser D. Posthuma EF, et al. Leukemia. 2000 May;14(5):859-62. doi: 10.1038/sj.leu.2401774. Leukemia. 2000. PMID: 10803518

4

Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.

Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH. Posthuma EF, et al. Biol Blood Marrow Transplant. 2004 Mar;10(3):204-12. doi: 10.1016/j.bbmt.2003.11.003. Biol Blood Marrow Transplant. 2004. PMID: 14993886 Free article.

5

HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia.

Rutten CE, van Luxemburg-Heijs SA, Griffioen M, Marijt EW, Jedema I, Heemskerk MH, Posthuma EF, Willemze R, Falkenburg JH. Rutten CE, et al. Among authors: posthuma ef. Leukemia. 2008 Jul;22(7):1387-94. doi: 10.1038/leu.2008.90. Epub 2008 Apr 17. Leukemia. 2008. PMID: 18418406

6

Conditional relative survival among adult patients with chronic myeloid leukemia in the tyrosine kinase inhibitor era: a population-based study in the Netherlands.

Ector GICG, Visser O, Posthuma EFM, Westerweel PE, Janssen JJWM, Blijlevens NMA, Dinmohamed AG. Ector GICG, et al. Leukemia. 2021 Nov;35(11):3291-3294. doi: 10.1038/s41375-021-01174-9. Epub 2021 Feb 18. Leukemia. 2021. PMID: 33603145 No abstract available.

7

The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018.

Maas CCHM, van Klaveren D, Ector GICG, Posthuma EFM, Visser O, Westerweel PE, Janssen JJWM, Blijlevens NMA, Dinmohamed AG. Maas CCHM, et al. Br J Haematol. 2022 Mar;196(5):1219-1224. doi: 10.1111/bjh.17989. Epub 2021 Dec 5. Br J Haematol. 2022. PMID: 34865221 Free PMC article.

8

Real-world costs of chronic lymphocytic leukaemia in the Netherlands.

Holtzer-Goor KM, Bouwmans-Frijters CA, Schaafsma MR, de Weerdt O, Joosten P, Posthuma EF, Wittebol S, Huijgens PC, Mattijssen EJ, Vreugdenhil G, Visser H, Peters WG, Erjavec Z, Wijermans PW, Daenen SM, van der Hem KG, van Oers MH, Groot CA. Holtzer-Goor KM, et al. Among authors: posthuma ef. Leuk Res. 2014 Jan;38(1):84-90. doi: 10.1016/j.leukres.2013.10.029. Epub 2013 Nov 8. Leuk Res. 2014. PMID: 24268350

9

Improved relative survival in older patients with acute myeloid leukemia over a 30-year period in the Netherlands: a long haul is needed to change nothing into something.

Kaplan ZLR, van Leeuwen N, Posthuma EFM, Visser O, Huls G, van de Loosdrecht AA, Dinmohamed AG. Kaplan ZLR, et al. Leukemia. 2022 Feb;36(2):596-598. doi: 10.1038/s41375-021-01503-y. Epub 2022 Jan 17. Leukemia. 2022. PMID: 35039638 No abstract available.

10

Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.

Raa DGT, van der Straten L, van Gelder M, Kersting S, Levin MD, Mous R, van der Straaten HM, Nijziel MR, van der Spek E, Posthuma EFM, Visser HPJ, van der Klift M, de Heer K, Bellido M, Doorduijn JK, Bruns AHW, Raijmakers RAP, Kater AP; HOVON CLL study group. Raa DGT, et al. Leuk Lymphoma. 2022 Oct;63(10):2276-2289. doi: 10.1080/10428194.2022.2084731. Epub 2022 Jun 23. Leuk Lymphoma. 2022. PMID: 35737364

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

71 results

Search Page